JP2003342172A - Composition for reducing diabetic blood glucose level comprising capsaicinoidlike substance and use of capsaicinoidlike substance as reducing agent for diabetic blood glucose level - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a composition for reducing the blood glucose level in patients suffering from diabetes as a new use of a capsaicinoidlike substance (capsinoid). <P>SOLUTION: The composition for reducing the blood glucose level in the patients suffering from the diabetes comprises the capsaicinoidlike substance (capsinoid) represented by either one of general formulae (wherein, n is an integer of ≥1). The capsaicinoidlike substance (capsinoid) has strong reducing actions on the diabetic glucose level and resultantly provides the excellent composition for reducing the diabetic glucose level. <P>COPYRIGHT: (C)2004,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a composition containing a capsaicinoid-like substance for lowering the blood glucose level of diabetic patients and the use of the capsaicinoid-like substance as a blood glucose lowering agent in diabetic patients.

[0002]

2. Description of the Related Art Conventional capsaicinoids represented by capsaicin promote energy metabolism (Kazuo Iwai, Teruo Kawada, "Food Function of Spices" (Kazuo Iwai, Joji Nakatani)), Koseikan (1989), P.97. ) And other various biological functions, but their use was limited due to pungency and invasiveness. Capsaicin was found to be relatively highly toxic (the LD ₅₀ for oral administration was 118.8 mg / kg in male rats and 97.4 m in female rats).
g / kg, Saito: A. and Yamamo
to, M.M. (1996) J. Toxicol.
Sci. 21: 195-200) Reduction of the toxicity was also an important issue. Therefore, much research has been conducted on obtaining capsaicinoids with low pungency and low pungency while retaining the beneficial biological functions of the capsaicinoids.

Yazawa et al. Selected and fixed a new spicy pepper cultivar "CH-19 sweet" from the self-progeny of a spicy spicy variety "CH-19" obtained in Thailand (Yazawa).
Susumu, Noboru Suedo, Kana Okamoto, Takakazu Namiki (1989) Journal of Horticultural Society 58: 601-607), said "CH-19
In "sweet", capsaicin, dihydrocapsaicin,
It was found that a novel capsaicinoid-like substance (fatty acid ester of vanillyl alcohol: hereinafter abbreviated as "capsinoid") is accumulated in large amounts in place of known capsaicinoids including nordihydrocapsaicin, homocapsaicin and homodihydrocapsaicin. It was
For the structure of the capsinoid, see “Kobat.
a K. , Todo T .; , Yawa S. , Iw
ai K. Watanabe T .; 1998, J .;
Agr. Food Chem. , 46: 1695-16
97 "and" Kobata K., Sutoh.
K. , Todo T .; , Yawa S. , Iwai
K. Watanabe T .; 1999, J .; Na
tur. Prod. 62: 335-336 ".

The inventors of the present invention have disclosed in Japanese Patent Laid-Open No. 11-246478.
In the publication, it is disclosed that these capsinoids exhibit energy metabolism promotion, immunostimulatory action, etc. without exhibiting the pungency of conventional capsaicinoids. Further, Japanese Patent Laid-Open No. 2001-26538 also discloses that the above-mentioned capsinoid has an obesity-suppressing effect, a body fat accumulation-suppressing effect, and an adrenaline secretion-promoting effect.

Further, in the patent application (Japanese Patent Application No. 2000-308078) entitled "Composition for improving endurance containing a novel capsaicinoid-like substance", the present inventors have found that the above-mentioned capsinoid has a long-term endurance. It is described that it has an improving effect.

Each of the above-mentioned actions is also observed in capsaicin, but the point that the capsinoid can show the action of improving the endurance without showing the pungency and invasiveness which are the most remarkable biochemical properties of capsaicin. It is worth mentioning.

[0007] Furthermore, the inventors of the present invention described in JP-A-2001-158738 entitled "A novel analgesic, food and feed containing a capsaicinoid-like substance", although the capsinoid has an analgesic action comparable to that of capsaicin. The toxicity was extremely low compared to capsaicin, and 100 mg / kg of capsaicin killed half of the mice used in the experiment, whereas 300 mg / kg of capsinoid did not cause death in mice. I have disclosed that.

[0008] That is, the capsinoid of the present invention should be positioned as a functionally novel compound capable of exhibiting a new physiological action rather than merely a compound obtained by removing the pungency of capsaicin. Elucidation of biological functions is an interesting subject.

[0009]

DISCLOSURE OF THE INVENTION It is an object of the present invention to clarify a new biological function of capsinoid as a fatty acid ester of vanillyl alcohol represented by capsiate and dihydrocapsiate, and to apply it. The present invention provides a composition for lowering blood glucose level in diabetic patients as a new use of the capsinoid.

[0010]

Means for Solving the Problems In the process of elucidating the new biological function of the capsinoid of the present invention, the present inventors surprisingly found that the capsinoid determines the time of fasting blood sugar level rise in a diabetic model mouse. It was found that it has a delaying effect (diabetic blood sugar level lowering effect). Even more surprisingly, such a delaying effect of the blood glucose elevation period was not observed in capsaicin, which was characteristic of capsinoids. In addition, like capsaicin, capsinoids also have an adrenergic secretion-promoting effect in a very short period of time, but it is shown that the capsinoids have a blood glucose-lowering effect that may exceed them, despite such a short period of time. Was done. The above shows that the capsinoid of the present invention delays the time of rising fasting blood glucose level of a diabetic model animal, in other words, delays the progression of diabetes, and administers this to a diabetic patient to treat the disease. It shows that it can be used.

Therefore, the first aspect of the present invention is (1) the general formula:

[Chemical 3] Or

[Chemical 4] A composition for lowering blood glucose level in a diabetic patient, which comprises a capsaicinoid-like substance (capsinoid) represented by the formula (n is an integer of 1 or more).

In the above general formula, capsinoids in which n is 1 to 10, particularly n is 3, 4 or 5 are preferred, and especially the capsinoid is 4-hydroxy-3-methoxybenzyl (E) -8-methyl-6. -Nonenoate (4-
hydroxy-3-methybenzyl
(E) -8-methyl-6-nonenoate:
Capsiate) or 4-hydroxy-3-methoxybenzyl 8-methylnonanoate (4-hydrox
y-3-methoxybenzyl 8-methy
Those which are lnonanoate (dihydrocapsiate) can be easily prepared and can be preferably used. Therefore, the second and third aspects of the present invention include (2) a decrease in blood glucose level in a diabetic patient according to (1) above, which comprises a capsaicinoid-like substance in which n is 3, 4, or 5 in the above general formula. And (3) the capsaicinoid-like substance is 4-hydroxy-3-methoxybenzyl (E) -8-methyl-6-nonenoate or 4-hydroxy-3-methoxybenzyl 8-methylnonanoate. A composition for lowering blood glucose level in the diabetic patient according to the above (1), which is characterized by the above.

Depending on the form of the composition for lowering diabetic blood sugar level of the present invention, the capsinoid may be added to the composition for lowering diabetic blood sugar level of the present invention in the form of a plant or fruit accumulating the capsinoid. Fruits derived from the red pepper variety "CH-19 sweet" are suitable for that purpose.
Therefore, in the fourth and fifth aspects of the present invention, (4) the capsaicinoid-like substance is blended in the form of a plant or fruit containing the substance as a component. (5) The composition for reducing blood glucose level in a diabetic patient according to any one of (4) to (5), wherein the plant or fruit is derived from a pepper cultivar "CH-19 sweet". A composition for lowering blood glucose level in a patient.

The composition for lowering blood glucose level in diabetic patients of the present invention can be administered in the form of a drug, a food for humans, or a feed for animals other than humans. Therefore, the sixth to eighth aspects of the present invention include
(6) A composition for lowering blood glucose level in a diabetic patient according to any one of (1) to (5) above which is in the form of a medicine, and (7) above (1) to (5) which is in the form of a food product. (8) A composition for lowering blood glucose level in diabetic patients, and (8) A composition for lowering blood glucose level in diabetic animals according to any one of (1) to (5) above, which is in the form of feed. Is.

Furthermore, the capsinoid of the present invention can be used for the treatment of diabetic patients (including humans and non-human animals) in need of treatment for lowering the blood glucose level by treating them. Can be offered. Therefore, the ninth aspect of the present invention is (9) the capsaicinoid-like protein described in any one of (1) to (5) above for producing a drug to be administered to a diabetic patient in need of treatment for lowering blood glucose level. The use of substances.

As described above, it is now clear that the capsinoid of the present invention has a strong effect of delaying the fasting of blood glucose level in diabetic patients, and therefore, the capsinoid can provide an excellent diabetic blood glucose level lowering composition. . Originally, the capsinoid of the present invention is also contained in some capsicum varieties having a conventional spiciness, such as "Nikko" and "Goshiki" (Shin Yazawa et al. (1989) Journal of the Horticultural Society of Japan 58: 601-607). Humans have traditionally had eating experience. In particular, since the capsinoid is less toxic than capsaicin, it can be used as an additive for functional foods and feeds having a diabetic blood glucose level-lowering effect, or
It can be used as an active ingredient of a locally administered drug.

[0017]

BEST MODE FOR CARRYING OUT THE INVENTION First, regarding the term “diabetic patient” in the present specification, the term refers to a real diabetic patient or animal diagnosed as requiring active treatment for diabetes, as well as a diagnostic patient. Is not considered necessary to aggressively treat diabetes, but has a relatively high blood glucose level near the risk level, or has a genetic predisposition to diabetes, and thus may potentially develop diabetes. Healthy people are also included.

Therefore, in the present specification, "treatment of diabetic patients" or "treatment for lowering blood glucose level" includes not only actual treatment of diabetic patients or animals but also diabetic treatment of latent diabetic patients as described above. Prophylactic treatment to prevent or delay the onset is also included.

The novel capsaicinoid-like substance (capsinoid) of the present invention can be prepared by purifying and separating from a capsicum plant and / or fruit containing the substance. Pepper used as a raw material for refining may be derived from a pepper cultivar having a conventional spiciness represented by "Nikko", "Goshiki", etc., but it is a non-spicy cultivar "CH-19 sweet" of the substance. It is particularly preferable because of its high content.

Purification / separation from the above-mentioned peppers is carried out by means of solvent extraction, various chromatography well known to those skilled in the art, various chromatography such as silica gel chromatography, preparative high performance liquid chromatography, etc., alone or in combination. For example, the method described in JP-A No. 11-246478 can be used. That is, simply, the above “CH-19 sweet”
After freeze-drying the fruit of 1., the capsinoid is extracted from the freeze-dried product with ethyl acetate. The obtained extract is concentrated under reduced pressure, and the concentrate is subjected to silica gel chromatography and eluted stepwise using a mixed liquid of n-hexane / ethyl acetate. After collecting and concentrating the fraction containing capsinoid, the concentrate is subjected to reverse phase chromatography to purify the capsinoid of the present invention.

The above-mentioned capsinoid can be synthesized, for example, by an esterification reaction using a corresponding activated fatty acid ester and vanillyl alcohol as starting materials, as described in JP-A No. 11-246478.
As a specific example, first, 8-methylnonanoic acid is reacted with thionyl chloride, and the resulting activated ester is reacted with vanillyl alcohol to give 4-hydroxy-3-methoxybenzyl 8-methylnonanoate (dihydrocapsiate). ) Can be obtained.

Further, the capsinoid can be easily prepared by a synthetic method using an enzyme. That is, for example, the desired capsinoid can be obtained by utilizing the reverse reaction of lipase using vanillyl alcohol and a compound such as a fatty acid ester corresponding to the desired compound and / or a triglyceride having the fatty acid as a substrate. This method is described in Japanese Patent Laid-Open No. 2000-312598.

In some cases, it is not necessary to purify / separate the capsinoid used as a compound into high purity,
The capsinoid is a new pepper cultivar "CH" containing them.
-19 sweet ”plants and / or fruits, their dried products, pulverized products or crude extracted substances can be added to the composition for lowering diabetic blood sugar level of the present invention and the like. That is, the new pepper cultivar "CH-19 sweet" contains almost no capsaicinoid that has pungency and invasiveness, and instead contains a large amount of capsinoid (fatty acid ester of vanillyl alcohol) that does not have pungency, so that the diabetic blood glucose level is lowered. The fruits, etc. derived from the variety may be directly blended with foods, feeds, pharmaceuticals, etc. for the purpose of action, or the fruits, etc. may be subjected to simple physical and / or chemical treatments such as drying, crushing and rough extraction. The composition of the present invention can be compounded only by doing this. In the present specification, the term “form of plant or fruit” means not only the plant and / or fruit as they are but also a very simple physical and / or chemical method such as drying, crushing or rough extraction. It also includes forms that have undergone physical processing.

The capsinoid of the present invention can be effectively used for the treatment of diabetes based on its excellent effect of delaying the rising time of the blood glucose level in the fasting state of diabetic patients.

That is, the composition containing the capsinoid of the present invention can be administered orally or parenterally, and by formulating into a form suitable for such administration, it is used as a drug for treating diabetic patients. be able to.

In clinical use of the capsinoid of the present invention, it is possible to add pharmaceutically acceptable additives in accordance with the dosage form and to administer it after various preparations. As the additive in that case, various additives usually used in the field of formulation can be used, for example, gelatin, lactose, sucrose, titanium oxide, starch, crystalline cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, corn starch, micro. Crystalline wax, white vaseline, magnesium aluminometasilicate, anhydrous calcium phosphate, citric acid, trisodium citrate, hydroxypropyl cellulose, sorbitol, sorbitan fatty acid ester, polysorbate, sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil, polyvinylpyrrolidone, Magnesium stearate, light anhydrous silicic acid, talc, vegetable oil, benzyl alcohol, gum arabic, propylene glycol, polyalkylene glycol, shik Dextrin or hydroxypropyl cyclodextrin and the like.

The dosage form formulated as a mixture with these additives is, for example, a solid preparation such as tablet, capsule, granule, powder or suppository; or, for example, syrup, elixir or injection. Liquid formulations are mentioned, which can be prepared by the usual methods in the field of formulation. For liquid formulations,
It may be in the form of being dissolved or suspended in water or another suitable medium at the time of use. In particular, in the case of an injection, if necessary, it may be dissolved or suspended in physiological saline or glucose solution, and a buffer and a preservative may be added.

These preparations may contain the capsinoid of the present invention in a proportion of 1 to 100% by weight, preferably 10 to 80% by weight, based on the total amount of the drug.

When the capsinoid having a diabetic blood glucose level-lowering effect of the present invention is used in a clinical setting, the dose and frequency of administration are determined by the sex of the patient, age, weight, degree of symptom and kind of intended treatment. Generally, in the case of oral administration, 1 to 50 mg / kg per day for an adult is divided into 1 to several times, and in the case of parenteral administration, it is 1 to 1 depending on the range.
It is preferable to administer 0 mg / kg in 1 to several divided doses.

Furthermore, the capsinoid of the present invention or a plant containing the same can give a functional food having a diabetic blood sugar level-lowering effect by adding them to food.

That is, the capsinoid of the present invention can be optionally added to various foods such as solid, liquid, sol, gel, powder and granular foods. The addition can be performed by any production method known in the art, for example, various solid foods; liquid foods such as sports drinks, by the method described in JP-A No. 11-246478. It can be easily added / blended to retort foods such as red bean porridge. In the food, the non-pungent property of the capsinoid of the present invention acts extremely advantageously in that the taste of the food containing the substance is not destroyed.

The capsinoid can also be used after being processed into a food additive form. As the shape and manufacturing method of the food additive containing the capsinoid, any known method to those skilled in the art may be adopted. For example, the above-mentioned additives can be produced by mixing, granulating or encapsulating the capsinoid of the present invention together with various excipients such as dextrin, corn starch and lactose, and auxiliary materials such as emulsifiers.

The capsinoids contained in the food ingredients are
As described above, it does not necessarily have to be sufficiently purified. That is, for example, "CH-19 sweet" itself (untreated product), which is a non-spicy fixed variety of capsicum described above (untreated product), a dried product or a pulverized product thereof, or an alcohol such as ethyl acetate or ethanol, or an emulsifier for foods, It may be contained as an extract of "CH-19 sweet" by various solvents commonly used in the art for extracting components from natural products.

Specific examples of the food containing the capsinoid of the present invention include orange concentrated fruit juice (0.2 parts by weight), sugar (1.8 parts by weight) and isomerized sugar (5.5 parts by weight), Citric acid (0.14 parts by weight), common salt (0.08 parts by weight), sodium citrate (0.07 parts by weight), potassium chloride (0.04 parts by weight), monobasic calcium phosphate (0.013 parts by weight) , Sodium glutamate (0.
004 parts by weight), magnesium chloride (0.003 parts by weight), ascorbic acid (0.1 parts by weight), cloudy (0.1 parts by weight), emulsified fragrance (0.01 parts by weight), essence (0.2 parts by weight) Part), the capsinoid of the present invention (0.
A sports drink consisting of (05 parts by weight) and the balance of water; further rice Koshihikari (4.2 parts by weight), white rice Koshihikari (4.8 parts by weight), Hokkaido azuki (1.6 parts by weight), sugar (0. 5 parts by weight), salt (0.1 parts by weight), "CH-
Examples include red bean porridge with a retort-pouch consisting of "19 sweet" fruits (2 parts by weight) and the balance water.

Further, the capsinoid of the present invention provides a feed having a diabetic blood glucose level lowering by blending them in the feed of animals.

That is, the capsinoid of the present invention can be arbitrarily incorporated into various feeds such as solid, liquid, sol, gel, powder and granular feeds. Those skilled in the art will readily understand that the person skilled in the art can achieve this by using a method essentially equivalent to the method of adding the substance to a food product or by appropriately modifying it.

The above-mentioned pepperless fixed variety "CH-19 sweet" of peppers has been applied for variety registration (Application No. 11601) to the Seedling Management Center of the Ministry of Agriculture, Forestry and Fisheries, and is available from this institution.

Hereinafter, the present invention will be described in detail with reference to examples, but the examples do not limit the present invention.

[0039]

EXAMPLES Example 1: Capsinoid dose and low blood glucose level
Lower action Six-week-old KK-A ^y / Ta Jc1 (hyperglycemic model) male mice were housed in one cage per cage.
MF (manufactured by Oriental Yeast Co., Ltd.) was pair-fed as the feed, and the conditions of light-dark reversal (light period 18: 00-00)
Preliminary breeding was carried out for 12 days until the start of administration at 06:00 and at 06: 00-18: 00 in the dark period. The blood glucose level was regularly measured during preliminary breeding, and the mice were divided into 3 groups (7 mice per group) so that the mean value and the standard deviation of the blood glucose level did not differ significantly.

A solution for administration of the test substance was prepared by adding 10 mg of the capsinoid of the present invention (synthetic product, capsiate: dihydrocapsiate≈2: 1) to 99.5% ethanol 1
Dissolve in 50 μl and add 50% Tween 80 to it.
Add 0 μl and mix well with Vortex.
Aline (0.85%) was added to fill up to 5 ml (the final concentration of capsinoid was 2 mg / m 2.
l). Capsaicin (2 mg / ml) was similarly prepared. In the base (Vehicle) administration group, 99.
150 μl of 5% ethanol and 5 of Tween 80
Saline (0.85%) was added to 00 μl and 5 ml was added.
To prepare a control base solution.

The blood glucose level of the mouse is 250 to 270 mg.
Administration of the test substance was started when the value reached / dl. The administration groups were the capsinoid administration group of the present invention, the capsaicin administration group, and the base administration group (control). The dose of the test substance was adjusted to 10 mg per kg of mouse body weight as the amount of capsinoid or capsaicin (the dose was calculated based on 38-40 g which is the average weight of mice at the start of the test). The administration was performed by daily oral gavage for 28 days using a stainless steel sonde (however, 6 days a week, 1 day off). The same amount of base solution was similarly administered to the control base administration group. In order to quantify the fasting blood glucose concentration, blood was collected from the mice 9 times in total during the 4 weeks from the start of administration to the end of administration. Ie every Tuesday and Friday week 2
Fasting of the mouse was started at 7:30 am, and blood was collected from the orbital venous plexus at 10 o'clock using a glass capillary (anticoagulant: sodium fluoride). The blood glucose concentration was measured using glucose CII test Wako (mutarotase GOD method: Wako Pure Chemical Industries, Ltd.) using the collected blood as a sample. As the measurement result, the average and standard deviation of the blood glucose level (blood glucose concentration) of each experimental group were calculated, and S
Evaluation was carried out by performing a significant difference test (significance level 5%) by the student's t-test.

Results At the age of 6 to 9 weeks when the blood glucose level starts to rise, orally capsinoid or capsaicin is orally administered, and when the blood glucose level starts to rise as compared with the base administration group (control), the plasma glucose concentration value, etc. It was observed whether or not there was a difference. As a result of collecting blood over time and measuring plasma glucose concentration, a high blood glucose level was always observed in the capsaicin administration group from the start to the end of administration. The blood glucose level on the 21st day of administration was 289.6 ± 102.4 mg / dl on average in the base administration group, 311.0 ± 87.4 mg / dl on average in the capsaicin administration group,
Average of capsinoid administration group is 228.4 ± 53.7 mg
As a result of statistical analysis, a significant difference (P = 0.041) was observed between the base administration group and the capsinoid administration group. The results are summarized in Table 1 and FIG. In Table 1, V
“Electle” represents a base administration group, “Capsaicin” or “Cap” represents a capsaicin administration group, and “CLS-B” represents a capsinoid administration group of the present invention.

[0043]

[Table 1]

[0044]

INDUSTRIAL APPLICABILITY The capsaicinoid-like substance (capsinoid) of the present invention has a strong diabetic blood glucose lowering action, and therefore can provide an excellent diabetic blood glucose lowering composition. In particular, since the capsinoid is less toxic than capsaicin, it can be used as an additive of a functional food or feed having a diabetic blood glucose lowering effect, or as an active ingredient of an orally / topically administered drug. .

[Brief description of drawings]

FIG. 1 is a diagram showing blood glucose level data of KK-A ^y mice after administration of the capsaicinoid-like substance (capsinoid) of the present invention.

   ─────────────────────────────────────────────────── ─── Continued front page    (72) Inventor Shuichi Hashizume             2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama-shi, Kanagawa             Morinaga & Co., Ltd. Research Institute (72) Inventor Masatoshi Kato             2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama-shi, Kanagawa             Morinaga & Co., Ltd. Research Institute (72) Inventor Hiroyuki Inagaki             2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama-shi, Kanagawa             Morinaga & Co., Ltd. Research Institute (72) Inventor Ryoichi Ito             2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama-shi, Kanagawa             Morinaga & Co., Ltd. Research Institute (72) Inventor Mariko Yoshikawa             2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama-shi, Kanagawa             Morinaga & Co., Ltd. Research Institute (72) Inventor Yuko Setoguchi             2-1-1 Shimosueyoshi, Tsurumi-ku, Yokohama-shi, Kanagawa             Morinaga & Co., Ltd. Research Institute F-term (reference) 4C088 AB50 BA07 BA08 MA43 MA52                       NA14 ZC35                 4C206 AA01 AA02 DB06 DB07 KA01                       MA04 MA72 MA75 NA14 ZC35

Claims (9)

[Claims] 1. A general formula: Or [Chemical 2] (In the formula, n is an integer of 1 or more.) A composition for lowering blood glucose level in a diabetic patient, which comprises a capsaicinoid-like substance represented by the formula. 2. The composition for lowering the blood glucose level in a diabetic patient according to claim 1, which contains a capsaicinoid-like substance in which n is 3, 4, or 5 in the above general formula. 3. The capsaicinoid-like substance is 4-
Hydroxy-3-methoxybenzyl (E) -8-methyl-6-nonenoate or 4-hydroxy-3-methoxybenzyl 8-methylnonanoate, which lowers blood glucose level in diabetic patients according to claim 1. Composition for. 4. The blood sugar in a diabetic patient according to claim 1, wherein the capsaicinoid-like substance is mixed in the form of a plant or fruit containing the substance as a component. Composition for lowering value. 5. The composition for lowering blood glucose level in a diabetic patient according to claim 4, wherein the plant or fruit is derived from a red pepper cultivar “CH-19 sweet”. 6. The composition for lowering blood glucose level in a diabetic patient according to any one of claims 1 to 5, which is in the form of a medicine. 7. The composition for lowering the blood glucose level in a diabetic patient according to claim 1, which is in the form of a food. 8. The composition for lowering the blood glucose level in a diabetic animal according to claim 1, which is in the form of a feed. 9. A method for producing a drug to be administered to a diabetic patient in need of treatment for lowering blood sugar level.
Use of the capsaicinoid-like substance according to any one of 1.